Literature DB >> 29054275

Comparison of Valsalva Maneuver, Amyl Nitrite, and Exercise Echocardiography to Demonstrate Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy.

Chadi Ayoub1, Jeffrey B Geske1, Carolyn M Larsen1, Christopher G Scott2, Kyle W Klarich1, Patricia A Pellikka3.   

Abstract

Guidelines recommend exercise stress echocardiogram (ESE) for patients with hypertrophic cardiomyopathy (HC) if a 50 mm Hg gradient is not present at rest or provoked with Valsalva or amyl nitrite, to direct medical and surgical management. However, no study has directly compared all 3 methods. We sought to evaluate efficacy and degree of provocation of left ventricular outflow gradients by ESE, and compare with Valsalva and amyl nitrite. In patients with HC between 2002 and 2015, resting echocardiograms and ESEs within 1 year were retrospectively reviewed. Gradients elicited by each provocation method were compared. Rest and ESE were available in 97 patients (mean age 54 ± 18 years, 57% male); 78 underwent Valsalva maneuver and 41 amyl nitrite provocation. Median gradients (interquartile range) were 10 mm Hg (7,19) at rest, 16 mm Hg (9,34) with Valsalva, 23 mm Hg (13,49) with amyl nitrite, and 26 mm Hg (13,58) with ESE. ESE and amyl nitrite were able to provoke obstruction (≥30 mm Hg) and severe obstruction (≥50 mm Hg) more frequently than Valsalva. In patients with resting gradient <30 mm Hg (n = 83), provocation maneuvers demonstrated dynamic obstruction in 51%; in those with Valsalva gradient <30 mm Hg (n = 57), ESE or amyl nitrite provoked a gradient in 44%; and in those with amyl nitrite gradient <30 mm Hg (n = 20), ESE provoked a gradient in 29%. No demographic or baseline echocardiographic parameter predicted provocable obstruction. In conclusion, ESE is clinically useful; however, different provocation maneuvers may be effective in different patients with HC, and all maneuvers may be required to provoke dynamic obstruction in symptomatic patients.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29054275     DOI: 10.1016/j.amjcard.2017.08.047

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

Review 1.  Mitral Valve Disease in Hypertrophic Cardiomyopathy:Evaluation and Management.

Authors:  C Charles Jain; Darrell B Newman; Jeffrey B Geske
Journal:  Curr Cardiol Rep       Date:  2019-10-31       Impact factor: 2.931

2.  Biomarker changes with systolic anterior motion of the mitral valve in cats with hypertrophic cardiomyopathy.

Authors:  Joonbum Seo; Jessie Rosie Payne; Jose Novo Matos; Wesley Wynne Fong; David J Connolly; Virginia Luis Fuentes
Journal:  J Vet Intern Med       Date:  2020-08-21       Impact factor: 3.333

3.  Squat-to-stand provocation of dynamic left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: a case report.

Authors:  Lillian T Peng; D Brian Newman; Jeffrey B Geske
Journal:  Eur Heart J Case Rep       Date:  2020-12-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.